Safe & secure VitaFOXO wallet
Take control of your VitaFOXO assets with complete confidence in the Trezor ecosystem.
- Secured by your hardware wallet
- Use with compatible hot wallets
- Trusted by over 2 million customers
Send & receive your VitaFOXO with the Trezor Suite app
Send & receive
Trezor hardware wallets that support VitaFOXO
Sync your Trezor with wallet apps
Manage your VitaFOXO with your Trezor hardware wallet synced with several wallet apps.
Trezor Suite
MetaMask
Rabby
Supported VitaFOXO Network
- Base
Why a hardware wallet?
Go offline with Trezor
- You own 100% of your coins
- Your wallet is 100% safe offline
- Your data is 100% anonymous
- Your coins aren’t tied to any company
Online exchanges
- If an exchange fails, you lose your coins
- Exchanges are targets for hackers
- Your personal data may be exposed
- You don’t truly own your coins
How to VITAFOXO on Trezor
Connect your Trezor
Open a third-party wallet app
Manage your assets
Make the most of your VITAFOXO
Trezor keeps your VITAFOXO secure
Protected by Secure ElementThe best defense against both online and offline threats
Your tokens, your controlAbsolute control of every transaction with on-device confirmation
Security starts with open-sourceTransparent wallet design makes your Trezor better and safer
Clear & simple wallet backupRecover access to your digital assets with a new backup standard
Confidence from day onePackaging & device security seals protect your Trezor’s integrity
This project will design a new RNA therapeutic that nudges the longevity-linked FOXO3 gene into its health-promoting form to halt the tissue breakdown behind degenerative disc disease—opening a precise, scalable route to drugs that extend healthspan.
Dr. Lorna Harries’ lab has identified an innovative way to modulate FOXO3, a well known and yet undrugged longevity target, and propose leveraging it to address chronic lower back pain stemming from degenerative disc disease. They plan to make short, lab-made modified RNA molecules (antisense oligonucleotides) that selectively switch FOXO3’s “good” message on, first in human cells and mini-disc models. Success would yield 1) a lead drug candidate, 2) proof it can restore disc health, and 3) the data needed for patenting and further development. The same molecules could later be adapted to treat many other age-related conditions, helping people stay healthy for longer.